Home › Funds › Bain Capital Life Sciences Investors, LLC › ANNX
Bain Capital Life Sciences Investors, LLC position in ANNX
ANNEXON INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 4,437,731 shares of ANNX (ANNEXON INC) in its Q3 2026 13F filing — a position valued at US$18.8M, representing 1.29% of its reported portfolio and ranking #16 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed ANNX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's ANNX position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in ANNX in Q3 2023 at 5,701,926 shares (US$13.5M). The position peaked in Q1 2024 at 8,703,268 shares, worth US$62.4M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 4,437,731 shares valued at US$18.8M. Notable position changes include a 41% increase in Q4 2023 (shares rose 58% over the following quarter), a 38% trim in Q4 2024 (shares fell 62% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.70M | $13.46M | New |
| Q4 2023 | 8.06M | $36.60M | Add |
| Q1 2024 | 8.70M | $62.40M | Add |
| Q2 2024 | 8.45M | $41.40M | Reduce |
| Q3 2024 | 8.45M | $50.02M | Hold |
| Q4 2024 | 5.25M | $26.93M | Reduce |
| Q1 2025 | 5.25M | $10.13M | Hold |
| Q2 2025 | 5.25M | $12.60M | Hold |
| Q3 2025 | 5.25M | $16.01M | Hold |
| Q4 2025 | 5.25M | $26.35M | Hold |
| Q1 2026 | 5.21M | $28.88M | Reduce |
| Q2 2026 | 4.44M | $25.34M | Reduce |
| Q3 2026 | 4.44M | $18.77M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANNX and 13F data
ANNX (ANNEXON INC) is a Health Care company. 40 other funds we track also report a position in ANNX — the largest reported positions include Redmile Group, LLC (US$67.8M), BVF INC/IL (US$49.7M), MAK CAPITAL ONE LLC (US$33.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANNX
- Redmile Group, LLC 11.87M sh · $67.78M · Q2 2026
- BVF INC/IL 8.70M sh · $49.67M · Q2 2026
- MAK CAPITAL ONE LLC 5.86M sh · $33.47M · Q2 2026
- Bellevue Group AG 4.10M sh · $23.41M · Q2 2026
- MPM BioImpact LLC 3.54M sh · $20.24M · Q2 2026
- GREAT POINT PARTNERS LLC 3.50M sh · $19.98M · Q2 2026
- Palo Alto Investors LP 2.95M sh · $16.83M · Q2 2026
- Opaleye Management Inc. 1.71M sh · $9.79M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held ANNX?
Bain Capital Life Sciences Investors, LLC has disclosed ANNX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in ANNX?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 4.44M shares of ANNX (ANNEXON INC), valued at $18.77M, representing 1.29% of its reported portfolio and ranking #16.
Has Bain Capital Life Sciences Investors, LLC been buying or selling ANNX?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in ANNX. The position peaked in Q1 2024 at 8.70M shares.
Which other funds hold ANNX?
Other major institutional holders of ANNX include Redmile Group, LLC, BVF INC/IL, MAK CAPITAL ONE LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.